Gemcitabine hydrochloride, 99%, a DNA synthesis inhibitor with IC50s of 37.6, 42.9, 92.7, 89.3 and 131.4 nM in BxPC-3, Mia Paca-2, PANC-1, PL-45 and AsPC-1 cells, respectively

Name: Gemcitabine hydrochloride, 99%, a DNA synthesis inhibitor with IC50s of 37.6, 42.9, 92.7, 89.3 and 131.4 nM in BxPC-3, Mia Paca-2, PANC-1, PL-45 and AsPC-1 cells, respectively | 122111-03-9
Brand: J&K Chemical
SKU: JK271269_250_MG
Price: 165.0 USD
Availability: OutOfStock

Cat. No JK271269_250_MG

Vendor: J&K Chemical

Product Information

Product Name

Gemcitabine hydrochloride, 99%, a DNA synthesis inhibitor with IC50s of 37.6, 42.9, 92.7, 89.3 and 131.4 nM in BxPC-3, Mia Paca-2, PANC-1, PL-45 and AsPC-1 cells, respectively

Brand Name

J&K

Product Number

271269

CAS

122111-03-9

Molecular Formula

C9H11F2N3O4·HCl

Molecular Weight

299.66

SDS Document

View/Download

Certificate of Analysis (COA)

COA not found

General Information

Synonyms

2′-Deoxy-2′,2′-difluorocytidine

PubChem CID

60749

IUPAC Name

4-amino-1-(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-ylpyrimidin-2-one;hydrochloride

InChI Key

OKKDEIYWILRZIA-OSZBKLCCSA-N

SMILES

C1=CN(C(=O)N=C1N)C@H2C(C@@H(C@H(O2)CO)O)(F)F.Cl

Properties

Melting Point

292

Optical Activity

+46° to +49° (C=1, H2O)

Safety Information

GHS Symbols

Signal Word

Danger

Hazard Statement

H360

Precautionary Statement

P203

P280

P318

P405

P501

References

A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index

Publication Name: Liver international : official journal of the International Association for the Study of the Liver

Publication Date: 2025-09-06

DOI: 10.1111/liv.70181|10.1111/liv.70343

Integrated network pharmacology and RNA sequencing analysis to reveal the mechanisms of Qici Sanling decoction in the treatment of gemcitabine resistant bladder cancer

Publication Name: Journal of Pharmaceutical and Biomedical Analysis

Publication Date: 2025-09-01

DOI: 10.1016/j.jpba.2025.116885

A PP2A-mtATR-tBid axis links DNA damage-induced CIP2A degradation to apoptotic dormancy and therapeutic resistance in PDAC

Publication Name: Cancer Letters

Publication Date: 2025-09-01

DOI: 10.1016/j.canlet.2025.217790

Bioactive polymers as stimulus-responsive anti-metastatic combination agents to treat pancreatic cancer

Publication Name: Biomaterials

Publication Date: 2025-09

DOI: 10.1016/j.biomaterials.2025.123255

Decipher the single-cell level responses to chemotherapy in pancreatic ductal adenocarcinoma by a cross-time context graph model

Publication Name: Cancer Letters

Publication Date: 2025-08-28

DOI: 10.1016/j.canlet.2025.217751

Gemcitabine hydrochloride, 99%, a DNA synthesis inhibitor with IC50s of 37.6, 42.9, 92.7, 89.3 and 131.4 nM in BxPC-3, Mia Paca-2, PANC-1, PL-45 and AsPC-1 cells, respectively

Product Information

General Information

Properties

Safety Information

References

A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index

Integrated network pharmacology and RNA sequencing analysis to reveal the mechanisms of Qici Sanling decoction in the treatment of gemcitabine resistant bladder cancer

A PP2A-mtATR-tBid axis links DNA damage-induced CIP2A degradation to apoptotic dormancy and therapeutic resistance in PDAC

Bioactive polymers as stimulus-responsive anti-metastatic combination agents to treat pancreatic cancer

Decipher the single-cell level responses to chemotherapy in pancreatic ductal adenocarcinoma by a cross-time context graph model